Labiotech.eu

News and Trends 22 Jun 2022

US Toddlers and children to receive Covid-19 vaccine after emergency approval granted

Emergency authorization was granted for the use of the Pfizer-BioNTech Covid-19 vaccines on children from six months old to under five years of age. The US Food and Drug Administration made the authorization on Friday (June 17). All children ages 6 months and up are now eligible to receive the COVID-19 vaccine, following the US […]

June 22, 2022 - 3 minutesmins - By Liza Laws

News and Trends 22 Jun 2022

Rensselaer researchers make face masks to fight viruses

Researchers at Rensselaer Polytechnic Institute in Troy, NY, have developed N95 surgical face masks that are not just barriers to bacteria and viruses, but can also destroy them. The team said the antiviral, antibacterial masks can be worn for longer, creating less waste as the masks do not need to be replaced as frequently. Helen […]

June 22, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 22 Jun 2022

Cystic fibrosis in the crosshairs as Carbon Biosciences launches with $38M funding

Carbon Biosciences, a Longwood Fund founded biotech company developing parvovirus-derived gene therapies, has launched with $38 million of financing led by Agent Capital. Agent is joined by Longwood Fund, Astellas Venture Management LLC, the Cystic Fibrosis Foundation, Solasta Ventures, University of Tokyo Innovation Platform (UTokyoIPC), and Camford Capital. Massachusetts-based Carbon is harnessing novel parvovirus vectors […]

June 22, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 22 Jun 2022

From mugwort allergy to an effective vaccine?

A research team at MedUni Vienna in Austria says it has discovered key mechanisms of allergy to pollen from the common weed mugwort, which could lay the foundation for the development of the world’s first vaccine. Mugwort (Artemisia vulgaris) poses a serious problem for some people with allergies in places where the plant is common […]

June 22, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 22 Jun 2022

Galapagos to acquire CellPoint and AboundBio to advance cell therapies

Belgian headquartered biotech Galapagos NV has acquired CellPoint and AboundBio, a move the Belgian company said propels it into next-generation cell therapy. Galapagos said the acquisitions give it access to an innovative, scalable, decentralized and automated point-of-care cell therapy supply model as well as a next-generation fully human antibody-based therapeutics platform. Galapagos said the goal […]

June 22, 2022 - 5 minutesmins - By Jim Cornall

Best in Biotech 22 Jun 2022

The top psychedelic drug developers leading the market

Psychedelic drugs have the potential to become an effective treatment for crippling mental health conditions such as depression. Here are five of the top drug developers leading their particular niches in the emerging field of psychedelic medicines. For decades, research into the therapeutic properties of psychedelic drugs was almost snuffed out as recreational use of […]

June 22, 2022 - 7 minutesmins - By Jonathan Smith

News and Trends 21 Jun 2022

Drug to treat esophageal cancer approved in China

A new drug application for first-line treatment of unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) has been approved in China. Biopharmaceutical company Innovent Biologics Inc together with Eli Lilly and Company were jointly granted the approval for the supplemental new drug application for TYVYT, a sintilimab injection, combined with cisplatin plus […]

June 21, 2022 - 2 minutesmins - By Liza Laws

News and Trends 21 Jun 2022

New data demonstrates clinical potential of Inivata’s RaDaR technology for breast cancer

Data supporting the detection of minimal residual disease (MRD) has highlighted potential to provide an early predictor of tumor recurrence in patients who have had breast cancer. Liquid biopsy company Inivata announced the new data in support of its new RaDaR assay for the detection of MRD in those with high-risk hormone receptor-positive (HR+), human […]

June 21, 2022 - 3 minutesmins - By Liza Laws

News and Trends 21 Jun 2022

Treatment for highly-sensitized kidney transplant patients approved and recommended

Treatment offered by Hansa Biopharma for the densensitization of highly sensitized adults prior to kidney transplants from deceased donors has been recommended by the UK’s National Institute for Health and Care Excellence (NICE). NICE considers Idefirix (imlifidase), made by Hansa, a Swedish company that specializes in enzyme technology for rare immunological conditions, to be a […]

June 21, 2022 - 3 minutesmins - By Liza Laws

News and Trends 21 Jun 2022

Therorna funding to accelerate circRNA-based platform

Therorna Inc., a Chinese biotech company specializing in the development of circular RNA (circRNA) technology-based new vaccines and therapies, including for COVID-19, has completed a $42 million series A financing round. The funding was co-led by MSA Capital, with participation from Sherpa Healthcare Partners, 3H Health Investment, and existing investors Quan Capital and Cenova Capital. […]

June 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 21 Jun 2022

Elypta raises $21M to develop early detection test for all cancers

Elypta, a Swedish diagnostics company aiming to commercialize the first metabolism-based liquid biopsy for early detection of any cancer, has raised $21 million in a series A financing round led by Bonnier Ventures. “The series A is a pivotal moment for Elypta as it fully funds the development of our two leading indications,” said Karl […]

June 21, 2022 - 2 minutesmins - By Jim Cornall

conveyor belt of medical vials for scale up production

News and Trends 21 Jun 2022

Immuneel Therapeutics raises $15M and starts patient trials for CAR-T cancer therapies

Indian biotech start-up Immuneel Therapeutics has announced it has started patient dosing in a CAR-T trial named “IMAGINE.” The Indian company focuses on creating access to Chimeric Antigen Receptor T cell therapy (CAR-T) and other cellular immunotherapies for the management and treatment of cancers. The phase II trial is the first industry sponsored CAR-T trial […]

June 21, 2022 - 4 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

US Toddlers and children to receive Covid-19 vaccine after emergency approval granted

Rensselaer researchers make face masks to fight viruses

Cystic fibrosis in the crosshairs as Carbon Biosciences launches with $38M funding

From mugwort allergy to an effective vaccine?

Galapagos to acquire CellPoint and AboundBio to advance cell therapies

The top psychedelic drug developers leading the market

Drug to treat esophageal cancer approved in China

New data demonstrates clinical potential of Inivata’s RaDaR technology for breast cancer

Treatment for highly-sensitized kidney transplant patients approved and recommended

Therorna funding to accelerate circRNA-based platform

Elypta raises $21M to develop early detection test for all cancers

Immuneel Therapeutics raises $15M and starts patient trials for CAR-T cancer therapies

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!